A cluster randomised controlled trial of pharmacist led Statin Outreach Support (SOS) in primary care: Design and baseline characteristics

Contemporary Clinical Trials

Volumn 31, Issue 4, 2010, Pages 303-311

  Lowrie, Richard ^a   Morrison, Jill ^b   McConnachie, Alex ^b  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular; Outreach; Pharmacy; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHARMACIST; PRESCRIPTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG PRESCRIPTIONS; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; REGRESSION ANALYSIS; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC;

EID: 77953363885     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.03.010     Document Type: Article

References (34)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet 344 (1994) 1383-1389
2. Sacks F.M., et al., for the Cholesterol and Recurrent Events trial (CARE) Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
3. The long term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 339 (1998) 1349-1357
4. Shepherd J., et al., for the West of Scotland Coronary Prevention (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Eng J Med 333 (1995) 1301-1307
5. Downs J.R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Air Force/Texas Coronary Prevention Study (AFCAPS/TexCAPS). JAMA 279 (1998) 1615-1622
6. The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high risk individuals: a randomised placebo controlled trial. Lancet 360 (2002) 7-22
7. Shepherd J., et al., The PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease: a randomised controlled trial. Lancet 360 (2002) 1623-1630
8. The ALLHAT Collaborative research group. The antihypertensive and lipid-lowering treatment to prevent a heart attack trial (ALLHAT). JAMA 288 (2002) 2998-3007
9. Sever P.S., et al., for the ASCOT investigators. The Anglo-Scandanavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Lancet 361 (2003) 1149-1158
10. Serruys P.W., et al. A randomised placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty (FLARE). Eur Heart J 20 (1999) 58-69
11. Schwartz G.G., et al. Effect of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. The MIRACL study. J Am Med Assoc 287 (2002) 3215-3222
12. Athyros V.G., et al. Treatment with atorvastatin to the National Cholesterol Education Programme goal versus 'usual' care in secondary coronary disease prevention: the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
13. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. NICE technology appraisal vol. 94 (2006), NICE, London www.nice.org.uk
14. Primatesta P., and Poulter N.R. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 321 (2000) 1322-1325
15. ASPIRE steering group. A British Cardiac Society survey of the potential for the secondary prevention of coronary heart disease: ASPIRE (action on secondary prevention through intervention to reduce events) principal results. Heart 75 (1996) 334-342
16. Campbell N.C., Thain J., Deans H.G., et al. Secondary prevention in coronary heart disease: a baseline survey of provision and possibility in general practice. BMJ (1998) 1430-1434
17. EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-772
18. Whincup P., et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 88 (2002) 25-29
19. Fernie J.A., Termorshuizen F., Gottesch W., et al. Adherence to evidence based statin guidelines reduces the risk of hospitalisations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 7 (2006) 1-6
20. The Information Centre, QOF Achievement Data at Strategic Health Authority and England level. http://www.icservices.nhs.uk/qofdocuments/QOF0405_SHAs_ClinicalSummary.xls accessed 21st September 2006.
21. Anon. Physician compliance with published guidelines on lipid lowering (2007), Bandolier. http://www.medicine.ox.ac.uk/bandolier/booth/cardiac/statphys.html http://www.medicine.ox.ac.uk/bandolier/booth/cardiac/statphys.html
22. O'Brien T., Oxman A.D., Davis D.A., et al. Educational outreach visits: effects on professional practice and health care outcomes. The Cochrane Database of systematic reviews (2002) 1
23. Grimshaw J.M., Thomas R.E., MacLennan G., et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess vol. 8 (2004) 1-72 iii-iv
24. Law M.R., et al. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta analysis. BMJ 326 (2003) 1423-1429
25. Scottish Index of Multiple Deprivation (modified) http://www.gla.ac.uk/projects/platform/Deprivation%20Report%20Sep%202003.pdf).
26. Ridout M.S., Demetrio C., and Firth D. Estimating intraclass correlation for binary data. Biometrics 55 (1999) 137-148
27. Allender S, Peto V, Scarborough P et al. Coronary Heart Disease statistics July 2007. British Heart Foundation. From: www.heartstats.org (accessed 24 February 2008).
28. Moher M., Yudkin P., Wright L., et al. Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. BMJ 322 (2001) 1-7
29. Better Care, Better Value indicators. Department Of Health and NHS institute for innovation and improvement. Jan 2007.
30. Usher-Smith J.A., et al. Evaluation of the cost savings and clinical outcomes of switching patients from Atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract 61 (2007) 15-23
31. Anon. Which statin, what dose?. DTB 45 (2007) 5
32. Avorn J., and Soumerai S.B. Improving drug therapy decisions through educational outreach. A randomised controlled trial of academically based "detailing". N Engl J Med 308 (1983) 1457-1463
33. Avorn J., Soumerai S.B., Everitt D.E., Ross-Dengan D., Beers M.H., Sherman D., et al. A randomised trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 327 (1992) 168-173
34. McConnell T.S., Cushing A.H., Bankhurst A.D., Healy J.L., McIlvenna P.A., and Skipper B.J. Physician behaviour modification using claims data: tetracycline for upper respiratory infection. West J Med 137 (1982) 448-450